Last reviewed · How we verify
NCT07501702: ETNA
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Phase 2 trial testing Povetacicept in Myasthenia Gravis, Generalized in 30 participants. Not yet recruiting.
2 March 2029
Quick facts
| Lead sponsor | Vertex Pharmaceuticals Incorporated |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 16 April 2026 |
| Primary completion | 2 March 2029 |
| Estimated completion | 2 March 2029 |
Drugs / interventions tested
- Povetacicept — full drug profile →
- Placebo
Conditions studied
- Myasthenia Gravis, Generalized — all drugs for Myasthenia Gravis, Generalized →
Sponsor
Vertex Pharmaceuticals Incorporated — full company profile →
Who can join
Adults 18 to 80, any sex, with Myasthenia Gravis, Generalized. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07501702
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Povetacicept
Trials testing the same drug.
- NCT07204275 — A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropat · Phase 2, PHASE3 · recruiting
- NCT07010406 — A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Present · Phase 1 · completed
- NCT06564142 — Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) · Phase 3 · active not recruiting
- NCT05732402 — An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases · Phase 1, PHASE2 · active not recruiting
Other recruiting trials for Myasthenia Gravis, Generalized
Currently open trials in the same condition.
- NCT07072988 — Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC E · Phase 4 · recruiting
- NCT06909253 — Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis · recruiting
- NCT06455709 — Markers of Favorable Response to Complement Inhibitors Therapy · recruiting
- NCT04806620 — Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research · recruiting
- NCT05067348 — Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis · Phase 2 · recruiting
Other Vertex Pharmaceuticals Incorporated trials
Trials by the same sponsor.
- NCT05951205 — Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Ge · Phase 3 · withdrawn
- NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
- NCT07378865 — Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants · Phase 1 · recruiting
- NCT07349394 — Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants · Phase 1 · completed
- NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07501702 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vertex Pharmaceuticals Incorporated
- Last refreshed: 30 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07501702.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing